We are live on ! Find out more
SCPH

scPharmaceuticals
SCPH

Delisted

SCPH was delisted on the 6th of October, 2025.

Back to rankings

73 hedge funds and large institutions have $213M invested in scPharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 27 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,525% more call options, than puts

Call options by funds: $1.3M | Put options by funds: $36K

3.69% more ownership

Funds ownership: 79.78% → 83.47% (+3.7%)

10% less funds holding

Funds holding: 81 → 73 (-8)

19% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 27

27% less capital invested

Capital invested by funds: $291M → $213M (-$77.7M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

50% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 14

Holders
73
Holders Change
-8
Holders Change %
-9.88%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
7
Increased
22
Reduced
27
Closed
14
Calls
$1.3M
Puts
$36K
Net Calls
+$1.27M
Net Calls Change
+$717K

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$15M
2
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
+$3.05M
3
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM)
Texas
+$2.97M
4
ACM
AIGH Capital Management
Maryland
+$1.22M
5
AA
AlphaCentric Advisors
Puerto Rico
+$985K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$5.92M
2
EI
EAM Investors
California
-$2.71M
3
Walleye Capital
Walleye Capital
New York
-$1.05M
4
IC
Ikarian Capital
Texas
-$1.03M
5
JFG
Jefferies Financial Group
New York
-$673K

SCPH Hedge Fund Activity: Q3 2023 in Review

73 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q3 2023, worth a combined $213M — down 27% from $291M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of SCPH and 7 opened new positions — a net loss of 7 holders — while 27 trimmed existing stakes and 22 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $15M. The largest seller was Millennium Management, cutting an estimated $5.92M.

  • 73 institutional investors held scPharmaceuticals (SCPH) as of Q3 2023, down from 81 in Q2 2023.
  • Funds reported $213M of scPharmaceuticals stock for Q3 2023, down 27% quarter-over-quarter.
  • 7 funds opened new scPharmaceuticals positions in Q3 2023 and 14 closed out, a net change of -7 holders.
  • The largest scPharmaceuticals buyer in Q3 2023 was Rubric Capital Management (New York), an estimated $15M added.
  • The largest scPharmaceuticals seller in Q3 2023 was Millennium Management, an estimated $5.92M sold.

Based on aggregated 13F filings for Q3 2023.